The basolateral amygdala decodes visceral pain and itch via distinct circuits and molecules Authors: Qiuying Zhao, Yong-Chang Li, Jia-He Yao, Rui-Xia Weng, Qianqian Chen, Xue Xu, Shufen Hu, Hong-Hong Zhang, Ying Zhang, Rui Li, Guang-Yin Xu Published: 2026 ABSTRACT AbstractAs aversive sensations, visceral pain and itch are highly refractory to conventional treatments. Accumulating evidence suggests that the basolateral amygdala (BLA) is involved in pain and itch; however, how the BLA segregates visceral pain and itch remains unclear. Here, we identify two distinct neuronal populations within the BLA that selectively respond to visceral pain and itch in mice. These populations project to distinct downstream brain regions-the ventromedial hypothalamus (VMH) and dorsomedial striatum (DMS)-forming separate circuits that specifically regulate visceral pain and itch. Furthermore, function-labeled single cell sequencing demonstrates that Fgf2 and Notch2 are highly and selectively expressed in visceral pain- and itch-labeled neurons, respectively. Knockdown of these genes selectively attenuates visceral pain and itch. These findings emphasize the critical role of the BLA in sorting the processes of visceral pain and itch, providing insights into the neural mechanisms underlying different sensory processing and identifying potential therapeutic targets.Subject terms: Neural circuits, Pain Introduction The sensory transmission system plays a central role in the integration and regulation of internal and external perceptions1. As fundamental and essential sensory modalities, pain and itch together constitute a critical warning system for detecting potentially harmful stimuli2–5. Pain is typically elicited by actual or potential tissue damage, with peripheral signals transmitted via primary sensory neurons to the spinal cord and subsequently relayed to higher brain centers6,7. These signals are ultimately integrated and interpreted within the cerebral cortex and associated affective-cognitive networks, thereby triggering a range of adaptive defensive responses aimed at minimizing tissue injury8. Similarly, itch is also considered a protective sensation, primarily driving behaviors such as scratching9. However, the etiology of itch is more complex, encompassing not only localized cutaneous conditions but also a variety of systemic or visceral disorders, suggesting a neurobiological basis involving cross-system integration10. For decades, significant progress has been made in studies investigating pain and itch separately; nevertheless, substantial advances in research addressing both sensations together remain very limited. As a result, the mechanisms underlying the distinction and interaction between pain and itch have remained a central topic in sensory neuroscience. Several classical theoretical frameworks have been proposed, including the specificity theory, pattern theory, intensity theory, and brain network theory11–13. These models, from different perspectives, elucidate fundamental principles of sensory coding, providing a foundation for understanding spinal-level signal processing and offering important theoretical guidance for exploring supraspinal mechanisms involved in pain and itch. In recent years, advances in neural circuit tracing, optogenetics, and in vivo imaging technologies have provided increasing evidence that somatic pain and itch are differentially represented in higher brain centers13,14. This organizational principle of “cell population-specific encoding and circuit-specific transmission” provides strong experimental support for the discrimination of these two sensory modalities. Notably, most existing studies have focused almost exclusively on somatic pain and itch15,16, with comparatively little attention given to visceral sensations. Visceral pain, as a prototypical interoceptive signal, is characterized by diffuse localization, poor spatial resolution, and strong emotional components, and its neural coding mechanisms differ markedly from those of somatic pain17–20. However, the distinction, interaction, and central encoding of visceral pain and itch remain largely unexplored. This knowledge gap limits our understanding of the organizational principles of the interoceptive system and constrains the development of precise therapeutic strategies for related disorders. Therefore, systematically elucidating how the brain differentially identifies and encodes visceral pain and itch at the levels of cell types, neural circuits, and molecular mechanisms will not only advance the theoretical framework of sensory neuroscience but also provide critical insights and potential targets for mechanism-based interventions, with significant scientific and translational value. The basolateral amygdala (BLA), a key subregion of the amygdala, has been the focus of accumulating evidence suggesting its involvement in modulating visceral pain and itch processing21,22. However, direct evidence regarding whether the BLA serves as a critical hub for integration and sorting in distinguishing visceral pain from itch remains lacking. In particular, it has yet to be systematically elucidated whether neuronal populations within the BLA exhibit modality-specific segregation or shared coding resources in terms of their functional organization, and how their corresponding molecular signatures and downstream projection patterns support such encoding strategies. To address this question, we employed a multidisciplinary approach combining the Tet-off system with function-dependent laser capture microdissection sequencing (fLCM-seq) to dissect the differential encoding mechanisms of visceral pain and itch in the BLA at the levels of neuronal populations, neural circuits, and molecular pathways. By establishing a cross-scale research pipeline that links activity labeling, molecular profiling, and circuit output, this study not only promises to reveal how emotion-related brain regions achieve fine discrimination between distinct visceral sensory modalities but also provides a theoretical framework for understanding the central representation principles of aversive sensations. Here, we demonstrate that the BLA serves as a critical neural hub that differentially processes visceral pain and itch through distinct circuits and molecular signatures. We show that there are two functionally distinct neuronal populations in the BLA: BLAFgf2+ neurons that project to the VMH to selectively modulate visceral pain, and BLANotch2+ neurons targeting the DMS to specifically regulate itch. Results Glutamatergic neurons in BLA respond to both CRD and histamine (His) While the involvement of the BLA in processing pain and itch has been established separately, direct evidence supporting its involvement in visceral pain and itch processing remains unknown. Moreover, studies investigating the concurrent participation of the BLA in both visceral pain and itch are still scarce; therefore, we first sought to determine whether the BLA is engaged in both modalities in the same experimental framework. To identify the involvement of BLA in visceral pain processing, 6-week-old mice were subjected to colorectal distention (CRD) stimulation at 60 mmHg, administered in five trials with 3-minute inter-trial intervals, each lasting 20 seconds (Fig. 1A), followed by whole-brain c-Fos immunofluorescence. The expression of c-Fos was observed in the BLA, lateral hypothalamus (LH), paraventricular thalamic nucleus (PVT), ventromedial hypothalamic nucleus (VMH), paraventricular hypothalamic nucleus (PVH), prefrontal cortex (PFC) and insular cortex (IC) regions. Notably, the BLA exhibited the most pronounced c-Fos expression among these regions (Fig. 1B, C). Moreover, this finding was further confirmed in female mice, where c-Fos expression in the BLA was more pronounced than in the other regions examined (Supplementary Fig. 1A, B). To verify the types of BLA neurons activated by CRD stimulation, immunofluorescence staining was performed. The ratio of glutamate+ c-Fos+ to c-Fos+ neurons was 82.64% (Fig. 1D), and the ratio of GABA+ c-Fos+ to c-Fos+ was 10.75% (Fig. 1E). The results revealed that most of the activated neurons were glutamatergic neurons. In vivo fiber photometry recording showed that CRD at pressures of 20, 40, 60 and 80 mmHg resulted in calcium responses in glutamatergic neurons in the BLA (Fig. 1F, G). Glutamatergic neurons in basolateral amygdala were activated by CRD and His. A Schematic timeline of CRD-induced c-Fos expression. B Representative images showing c-Fos expression in the BLA, LH, PVT, VMH, PVH, PFC, IC of Sham-CRD and CRD mice. C Heatmap of c-Fos expression in BLA, LH, PVT, VMH, PVH, PFC, IC of Sham-CRD and CRD mice. ****P < 0.0001, ***P < 0.001, two-way ANOVA with Bonferroni test. n = 3 mice, two slices from each mouse. D Representative images of BLA showing co-localization of glutamate and c-Fos (left) and the percentage of co-localization in BLA (right, 82.64% ± 0.51%, n = 3 mice, three slices from each mouse). E Representative images of BLA showing co-localization of GABA and c-Fos (left) and the percentage of co-localization in the BLA (right, 10.75% ± 0.99%, n = 3 mice, three slices from each mouse). F Viral injection strategy with injection site (left) and flowchart (right) of calcium signal recording. G Heatmap (left), average Ca2+ transients (middle) of the BLAGlu, and averaged aera under curve of calcium activity (right) of the BLAGlu under CRD stimulation. n = 6 mice. H Schematic timeline of His-induced c-Fos expression. I Representative images showing c-Fos expression in BLA, PFC, DMS, PVT, IC, S1, ACC of PBS and His mice. J Heatmap of c-Fos expression in BLA, PFC, DMS, PVT, IC, S1, ACC of PBS and His mice. ****P < 0.0001, ***P < 0.001, two-way ANOVA with Bonferroni test. n = 3 mice, two slices from each mouse. K Representative images of BLA showing co-localization of glutamate and c-Fos (left) and the percentage of co-localization in the BLA (right, 82.06% ± 1.99%, n = 3 mice, three slices from each mouse). L Representative images of BLA showing co-localization of GABA and c-Fos (left) and the percentage of co-localization in the BLA (right, 12.64% ± 1.95%, n = 3 mice, three slices from each mouse). M Viral injection strategy with injection site (left) and flowchart (right) of calcium signal recording. N Heatmap (left), average Ca2+ transients (middle) of the BLAGlu and averaged aera under curve of calcium activity (right) of the BLAGlu under His stimulation. n = 6 mice. All data are presented as means ± SEM. Scale bar = 50 μm in all panels. Glu: glutamate. Next, itch induced by His stimulation was applied to mice, followed by whole-brain c-Fos staining (Fig. 1H). The expression of c-Fos was observed in the BLA, PFC, dorsomedial striatum (DMS), PVT, IC, primary somatosensory cortex (S1) and anterior cingulate cortex (ACC) regions, and the BLA exhibited the most pronounced c-Fos expression among these regions (Fig. 1I, J). Moreover, this finding was further confirmed in female mice, where the c-Fos expression in the BLA was more pronounced than in the other regions examined (Supplementary Fig. 1C, D). To verify the subtypes of neurons activated in the BLA, immunofluorescence staining was performed. The ratio of glutamate+ c-Fos+ to c-Fos+ neurons was 82.06% (Fig. 1K), and the ratio of GABA+ c-Fos+ to c-Fos+ neurons was 12.64% (Fig. 1L). Thus, His stimulation also predominantly activated glutamatergic neurons. Furthermore, immunofluorescence staining was also performed to identify the subtypes of neurons activated by chloroquine (CQ)-induced itch in the BLA. We found that the BLA glutamatergic neurons were significantly activated in the CQ-induced itch model (Supplementary Fig. 2). In addition, we also observed that the neuronal population in the BLA activated by CQ was distinct from that activated by His (Supplementary Fig. 3). In vivo fiber photometry recording showed that itch induced by His stimulation resulted in increased calcium activity in glutamatergic neurons in the BLA (Fig. 1M, N). These data indicated that the BLA glutamatergic neurons respond to both visceral pain and itch. Since the immunofluorescence staining also showed a lower proportion of activation within the GABAergic population in the BLA, chemogenetic manipulation of the GABAergic neurons was therefore performed to investigate the functional significance of these neurons in visceral pain and itch. Using chemogenetic manipulation (Supplementary Fig. 4A), we selectively inhibited or activated GABAergic neurons in the BLA. Both activation and inhibition of BLA GABAergic neurons produced no effect on the distention threshold (Supplementary Fig. 4B, C), and similarly, neither manipulation altered the bouts of scratching (Supplementary Fig. 4D, E). These findings suggest that BLA GABAergic neurons do not play a role in the regulation of these two sensory modalities. His- and CRD-activated neurons are two distinct ensembles in the BLA Next, we explored how the BLA glutamatergic neurons process both visceral pain and itch. Are they the same neurons or two completely distinct populations? As a foundation for understanding how BLA neural ensembles process visceral pain and itch information, we initially investigated their precise modulatory functions in each behavior. To characterize how visceral pain and itch are represented within BLA neural ensembles, we coupled the Tet-off system with c-Fos immunofluorescence staining (Fig. 2). Following co-injection of AAV2/9-TRE3g-mCherry and AAV2/9-c-fos-tTA into the BLA, mice were subjected to itch agent stimulation with His (100 μg in 10 μL) injected into the nape. Neuronal ensembles activated by His were labeled with mCherry. Subsequently, 1.5 hours prior to perfusion, CRD was applied, and CRD-activated BLA neuronal ensembles were labeled by c-Fos staining (Fig. 2A). To establish the optimal time window for the Tet-off system, we first evaluated multiple intervals (12 h, 24 h, and 36 h). Based on this evaluation, a 36-hour window was selected and subsequently validated, confirming its labeling specificity and efficacy for signal detection (Supplementary Fig. 5). Subsequently, the spatial distribution of His- and CRD-activated BLA neural ensembles was mapped via mCherry expression and c-Fos histological quantification revealed that 47.6% of these ensembles exclusively expressed itch-induced mCherry, 46.5% solely exhibited visceral pain-activated c-Fos, and 5.9% displayed co-expression of both markers (Fig. 2B, C). Quantitative analysis showed that the percentage of double-positive neurons for mCherry and c-Fos was significantly lower than that of single-positive neurons expressing either mCherry or c-Fos alone (Fig. 2D, E). However, the number of BLA cells activated by itch did not differ significantly from that activated by visceral pain (Fig. 2F). Following a similar experimental strategy outlined in Fig. 2A, we reversed the order of stimulation, labeling neurons activated by visceral pain with mCherry and labeling neurons activated by itch with c-Fos. The number of neurons positive for both mCherry and c-Fos was markedly lower than that of neurons positive for either marker alone, further confirming the specificity of the Tet-off system (Supplementary Fig. 6). Consistent with the findings in males, a statistical comparison in female mice showed that the proportion of neurons co-expressing mCherry and c-Fos was markedly lower than that of neurons expressing mCherry or c-Fos alone (Supplementary Fig. 7). To exclude the potential influence of topographical location, we further examined the BLA responses to somatic pain and itch stimuli that applied to the same anatomical site. As demonstrated using the Tet-off system, somatic pain and itch stimuli activated partially overlapping neuronal populations in the BLA (8.3% overlap, Supplementary Fig. 8). These findings demonstrate distinct processing mechanisms for pain and itch rather than topographical organization within the BLA. Moreover, we performed immunofluorescence to further verify the types of CRD- and His-labeled BLA neurons. The results revealed that both groups were predominantly glutamatergic neurons (Fig. 2G, H), which is consistent with previous findings that the neurons in the BLA activated by CRD and His are mainly glutamatergic neurons. Collectively, these findings demonstrated that the number of BLA cells positive for either mCherry or c-Fos alone was markedly higher than that of double-positive neurons, suggesting that CRD- and His-activated BLA neural ensembles are two distinct populations that selectively recognize visceral pain and itch signals. Representation of visceral pain and itch-activated neural ensembles in BLA. A Schematic depiction of the Tet-off viral system used alongside c-Fos immunostaining to label BLA cells responsive to His and CRD stimulation. B Representative fluorescence micrographs showing BLA cells in response to His and CRD, where mCherry (red) and c-Fos (green) indicate the respective populations. C Proportions of CRD & His co-labeled, His-labeled and CRD-labeled neuronal populations. D Compared with the fraction of neurons labeled with a single marker (88.95% ± 0.78%), the fraction of neurons that co-expressed mCherry and c-Fos (11.05% ± 0.78%) was significantly smaller. t5 = 49.803, ****P < 0.0001, paired Student’s t test, n = 6 brain slices from three mice per group. E The proportion of c-Fos+ neurons that co-stained for mCherry (11.27% ± 0.80%) was significantly less than that of neurons staining exclusively for c-Fos (88.73% ± 0.80%). t5 = 48.558, ****P < 0.0001, paired Student’s t test, n = 6 brain slices from three mice per group. F Numbers of BLA neuronal populations responsive to His and CRD, t5 = 0.835, P = 0.442, paired Student’s t test, n = 6 brain slices from three mice per group. G Representative fluorescence micrographs demonstrating co-labeling of His-labeled neurons or CRD-labeled neurons with glutamate immunostaining. H Glutamate co-localization rates in mCherry+ neurons (80.39% ± 2.06%) and Glutamate co-localization rates in c-Fos+ neurons (80.99% ± 2.66%). All data are presented as means ± SEM. Scale bar = 100 μm in (B, G), scale bar = 50 μm in zoomed image in (G). Glu: glutamate, ns: no significance. VMH received projections primarily from CRD-labeled BLA neurons rather than His-labeled BLA neurons, whereas DMS received projections primarily from His-labeled BLA neurons rather than CRD-labeled BLA neurons Given that visceral pain and itch activate two separate neuronal populations, these groups likely exhibit divergent projection patterns. To test this possibility, an anterograde tracing strategy was employed to selectively express GFP in either CRD- or His-labeled BLA neurons, allowing whole-brain visualization of GFP-tagged axon terminals. The mixture of AAV2/9-EF1α-DIO-Ypet-mGFP, AAV2/9-TRE3g-Cre, and AAV2/9-c-fos-tTA was microinjected into the BLA for function-dependent viral tracing (Fig. 3A), and examination of the injection sites confirmed that viral expression was restricted to the BLA region (Fig. 3B). Control injections of AAV2/9-hSyn-EGFP into the BLA revealed GFP-labeled axon terminals within the VMH, DMS, IC, PFC, and ACC. Quantitative analysis showed that the IC, PFC, and ACC received comparable projection intensities from both CRD- and His-labeled BLA neurons. Conversely, biased projection patterns emerged between these two ensembles: the VMH was innervated predominantly by CRD-labeled BLA neurons, whereas the DMS received inputs columns primarily from His-labeled BLA neurons (Fig. 3C–E). Additionally, we used a dual retrograde tracing approach to test whether the BLA neuronal populations that project to the VMH and to the DMS are distinct. Specifically, we injected a mixture of AAV2/9-DIO-EGFP and AAV2/9-fDIO-mCherry into the BLA, while the DMS and VMH received AAV2/R-hSyn-Cre and AAV2/R-hSyn-flp, respectively (Fig. 3F). We detected minimal co-localization among retrogradely labeled BLA neurons from DMS and VMH (Fig. 3G, H). These data demonstrate that BLA neurons projecting to the VMH are different from those projecting to the DMS, thereby reinforcing the idea that the BLA ensembles individually marked by CRD and His likewise project to both the VMH and DMS. To further validate the roles of the VMH and DMS as downstream targets of the BLA in mediating visceral pain and itch behaviors, respectively, fiber photometry recording was performed. A mixture of AAV2/9-DIO-Axon-GCaMP6s, AAV2/9-TRE3g-Cre, and AAV2/9-c-fos-tTA was injected into the BLA (Fig. 3I), with optical fibers targeting the VMH (Fig. 3J). As a primary downstream region of CRD-labeled neurons, the VMH exhibited a pronounced response to visceral pain, while remaining unresponsive to itch (Fig. 3K–M). Similarly, the same viral cocktail was infused into the BLA (Fig. 3N), with fibers aimed at the DMS (Fig. 3O). Conversely, the DMS, a major downstream region of His-labeled neurons, exhibited a robust response to itch but showed no response to visceral pain (Fig. 3P–R). These results indicated that CRD- and His-labeled BLA neurons exhibited distinct projection patterns. Projections of CRD-labeled BLA neurons to the VMH specifically respond to visceral pain whereas projections of His-labeled BLA neurons to the DMS specifically respond to itch. A Experimental scheme illustrating the viral protocol and timing used to trace the output pathways of CRD- and His-labeled BLA neuronal populations. B Representative view showing the viral injection site within the BLA. C Representative images showing axonal projections from blank control (top), CRD-labeled (middle), and His-labeled (bottom) BLA neurons. D Heatmap depicting the density of axon terminals in major downstream regions originating from CRD-labeled and His-labeled BLA populations. ***P < 0.001, two-way ANOVA followed by Bonferroni’s post hoc test, n = 6 brain slices from three mice per group. E Schematic illustrating the downstream targets of CRD-labeled (top) and His-labeled (bottom) BLA cells in selected brain structures. F Viral injection strategy of retrograde labeling of VMH and DMS. G Images depicting retrograde labeling of BLA neurons from VMH and DMS. H The percentage of co-localization in mCherry (6.66% ± 1.02%) and EGFP (5.12% ± 0.54%) positive neurons, respectively. I, J Schematic overview of calcium recording in axon terminals from CRD-labeled BLA cells in the VMH, along with a representative image showing GCaMP6s expression in these terminals. K Heatmap of calcium signals recorded from VMH axon terminals originating from CRD-labeled BLA cells, shown for CRD (left) and His (right) stimulation conditions. L Mean calcium transients in axonal boutons of CRD-labeled BLA neurons that innervate the VMH, evoked by CRD (green) or His (red). M Quantification of the AUC for ΔF/F calcium activity in axonal endings of BLA neurons labeled by CRD and projecting to the VMH, when exposed to CRD or His. F1,6 = 102.708, ***P < 0.001, two-way ANOVA followed by Bonferroni’s post hoc test, n = 7 mice in each group. N, O Schematic overview of calcium recording in axon terminals from His-labeled BLA cells in the DMS, along with a representative image showing GCaMP6s expression in these terminals. P Heatmap of calcium signals recorded from DMS axon terminals originating from His-labeled BLA cells, shown for His (left) and CRD (right) stimulation conditions. Q Mean calcium transients in axonal boutons of His-labeled BLA neurons that innervate the CRD, evoked by His (red) or CRD (green). R Quantification of the AUC for ΔF/F calcium activity in axonal endings of BLA neurons labeled by His and projecting to the DMS, when exposed to His or CRD. F1,6 = 48.237, ***P < 0.001, two-way ANOVA followed by Bonferroni’s post hoc test, n = 7 mice in each group. All data are presented as means ± SEM. Scale bar = 100 μm in all panels, ns: no significance. Manipulation of the projections from CRD-labeled BLA neurons to VMH or His-labeled BLA neurons to DMS specifically modulates visceral pain or itch behaviors Since CRD-labeled and His-labeled neurons exhibited distinct projection patterns to the VMH and DMS, we next assessed whether visceral pain and itch are differentially processed by the projections from CRD-labeled BLA neurons to the VMH and those from His-labeled BLA neurons to the DMS. We reasoned that these functionally distinct BLA neural ensembles transmit segregated information to specific downstream targets to drive modality-specific behaviors. To evaluate this functionally, pathway-specific chemogenetic manipulations were executed. Mice received bilateral BLA microinjections of a viral cocktail containing AAV2/9-c-fos-tTA blended with either AAV2/9-TRE3g-hM3Dq-mCherry, AAV2/9-TRE3g-hM4Di-mCherry, or control AAV2/9-TRE3g-mCherry, alongside guide cannula implantations over the VMH or DMS (Fig. 4A). We labeled BLA neurons with CRD and examined mCherry expression within the axon terminals that projected to the VMH (Fig. 4B). Following cannula-mediated administration of saline or CNO, we noted that chemogenetic activation of the projections from CRD-labeled BLA neural ensembles to the VMH remarkably lowered the visceral pain threshold without impairing itch behaviors (Fig. 4C, D). Conversely, when we chemogenetically inhibited the VMH-projecting axons of CRD-labeled BLA ensembles, visceral pain threshold was significantly elevated, whereas itch behaviors remained unaffected (Fig. 4E, F). Furthermore, we validated this finding in female mice by showing that manipulation of the VMH-directed projections originating from CRD-labeled BLA neurons selectively regulated visceral pain while leaving itch responses unaffected (Supplementary Fig. 9A–F). Furthermore, the same viral cocktail was delivered into the BLA (Fig. 4G). Similarly, we labeled BLA neurons with His and examined mCherry expression in their DMS-projecting axon terminals (Fig. 4H). Chemogenetic activation of the projections from His-labeled BLA ensembles to the DMS significantly potentiated itch behaviors, whereas chemogenetic inhibition significantly reduced itch behaviors; neither manipulation affected visceral pain responses (Fig. 4I–L). Similarly, in female mice, we showed that the projections from His-labeled BLA neurons to the DMS selectively modulated itch without affecting visceral pain (Supplementary Fig. 9G–L). Manipulation of the projections of CRD-labeled BLA neural ensembles to the VMH specifically modulates visceral pain, whereas manipulation of the projections of His-labeled BLA neural ensembles to the DMS specifically modulates itch. A Schematic depicting the viral approach and time course used to modulate the outputs of CRD-labeled BLA neuronal population toward the VMH. B Immunofluorescence images showing representative axonal endings within the VMH. C, D Selective chemogenetic activation of CRD-labeled BLA outputs directed to the VMH markedly decreased the visceral pain threshold (C) while leaving itch behavior unaffected (D). F1,14 = 10.620, **P = 0.003, two-way ANOVA followed by Bonferroni’s post hoc test, n = 8 mice in each group. E, F Selective chemogenetic inhibition of CRD-labeled BLA outputs directed to the VMH markedly increases visceral pain threshold (E) while leaving itch behavior unaffected (F). F1,14 = 26.307, ***P < 0.001, two-way ANOVA followed by Bonferroni’s post hoc test, n = 8 mice in each group. G Schematic depicting the viral approach and time course used to modulate the outputs of His-labeled BLA neuronal population toward the DMS. H Immunofluorescence images showing representative axonal endings within the DMS. I, J Selective chemogenetic activation of His-labeled BLA outputs directed to the DMS markedly increases the bouts of scratching (I) while leaving visceral pain behavior unaffected (J). F1,14 = 9.084, **P = 0.005, two-way ANOVA followed by Bonferroni’s post hoc test, n = 8 mice in each group. K, L Selective chemogenetic inhibition of His-labeled BLA outputs directed to the DMS markedly reduces the bouts of scratching (K) while leaving visceral pain behavior unaffected (L). F1,14 = 9.521, **P = 0.005, two-way ANOVA followed by Bonferroni’s post hoc test, n = 8 mice in each group. All data are presented as means ± SEM. Scale bar = 100 μm in all panels, ns: no significance. Fgf2 and Notch2 are distinctly expressed in CRD-labeled and His-labeled BLA neural ensembles Distinct BLA neural ensembles are recruited by visceral pain versus itch, a divergence presumably driven by unique molecular signatures. To characterize the molecular signatures of BLA populations labeled by CRD and His, we applied an approach called fLCM-seq (Fig. 5A). By integrating the Tet-off system with c-Fos immunostaining, these functionally segregated neural cohorts were selectively tagged, allowing for the high-precision isolation of CRD-labeled, His-labeled, and CRD & His co-labeled neurons at single-cell resolution using laser capture microdissection (Fig. 5B). We subsequently evaluated the transcriptomic variations among these three BLA subpopulations. Principal component analysis (PCA) was conducted subsequent to the selection of highly variable genes. The spatial distribution demonstrated that neurons belonging to the same functional ensemble grouped closely together into separate clusters, confirming that these three BLA neural ensembles possess highly distinct transcriptional profiles (Fig. 5C). Subsequently, we conducted a comprehensive statistical analysis to examine differential gene expression (DEG) across the three groups. Intriguingly, comparative analysis of gene expression patterns revealed that Fgf2 was selectively and highly enriched in the CRD-labeled population, whereas Notch2 exhibited specific and elevated expression in the His-labeled group (Fig. 5D–F). Notably, Fgf2 has been reported to play a crucial role in pain regulation, while Notch2 is associated with renal or hepatic itch23–26. By calculating differentially expressed genes (DEGs), we identified 30 genes specifically and highly expressed in the CRD-labeled group and 97 in the His-labeled group (Fig. 5G). Further Gene Ontology (GO) enrichment analysis highlighted that genes in the CRD-labeled group and genes in the His-labeled group were significantly enriched in biological processes related to the positive regulation of biological processes, response to stimulation, molecular function regulator and binding (Fig. 5H). Furthermore, Fgf2 and Notch2 were significantly enriched among upregulated genes in CRD-labeled and His-labeled neuronal ensembles, respectively (Fig. 5I). The top DEGs of CRD-labeled and His-labeled neuronal ensembles are presented in a table (Table S1). Strings analysis of the identified genes revealed that Fgf2 and Notch2 are functionally associated with a wide range of molecular partners (Fig. 5J). To further validate the specific expression of Fgf2 and Notch2 in the CRD-labeled and His-labeled neurons, respectively, we performed immunofluorescence staining. Our results demonstrated that 69.75% of CRD-labeled BLA neural populations expressed Fgf2, while only 5.25% of His-labeled BLA neural populations showed Fgf2 (Fig. 5K, L). Similarly, 75.75% of His-labeled BLA neural ensembles exhibited Notch2 expression, while merely 5.92% of CRD-labeled BLA neural ensembles showed Notch2 expression (Fig. 5M, N). These findings suggest that Fgf2 may play a specific role in visceral pain regulation, whereas Notch2 could be uniquely involved in itch modulation. Fgf2 and Notch2 are specifically expressed in CRD-labeled and His-labeled BLA neural ensembles, respectively. A Diagram showing the experimental fLCM-seq procedure. B Representative images of brain sections before (Pre) and after (Post) fLCM. C PCA plot demonstrating the differences across CRD-labeled, His-labeled, and CRD & His co-labeled neuronal ensembles. n = 3 mice in each group. D–F Volcano plots depicting differentially expressed genes (DEGs) identified in the CRD-labeled, His-labeled, and CRD & His co-labeled populations. Red dots indicate genes upregulated in the His-labeled population, green dots indicate genes upregulated in the CRD-labeled population, and yellow dots denote genes upregulated in the CRD & His co-labeled population. Differential expression was analyzed using DESeq2 based on a negative binomial distribution and a two-tailed Wald test, log2 fold change >4, p value < 0.05. G Venn diagrams depicting 30 genes with elevated expression in the CRD-labeled set and alongside 97 genes with elevated expression in the His-labeled set. H GO term enrichment assessment for the DEGs. I Heatmap showing DEGs that were enriched in the CRD- and His-labeled populations. J STRING (Search Tool for the Retrieval of Interacting Genes or Proteins) analysis of enriched gene sets in CRD-labeled and His-labeled neuronal populations. K Representative micrographs showing Fgf2 co-expression with CRD-labeled (left) and His-labeled (right) BLA cells. L Proportion of Fgf2 overlap with CRD-labeled and His-labeled BLA cells. t10 = 21.972, ****P < 0.0001, unpaired Student’s t test, n = 6 brain slices from three mice per group. M Representative micrographs showing Notch2 co-expression with CRD-labeled (left) and His-labeled (right) BLA cells. N Proportion of Notch2 overlap with His-labeled and CRD-labeled BLA cells. t10 = 21.373, ****P < 0.0001, unpaired Student’s t test, n = 6 brain slices from three mice per group. All data are presented as means ± SEM. Scale bar = 100 μm in all panels. Knockdown of Fgf2 in CRD-labeled BLA neurons projecting to VMH attenuates visceral pain whereas knockdown of Notch2 in His-labeled BLA neurons projecting to DMS inhibits itch Selective knockdown of Fgf2 expression was performed in CRD-labeled BLA neurons that project to the VMH, in order to further investigate its involvement in visceral pain modulation via the BLA-VMH circuit. A mixture of AAV2/9-DIO-mCherry-Fgf2 shRNA or scrambled shRNA and AAV2/9-c-fos-tTA was injected into BLA, whereas AAV2/R-TRE3g-Cre was microinjected into the VMH (Fig. 6A). Fgf2 knockdown significantly reduced mCherry co-localization with Fgf2-positive neurons compared to the scrambled control, leading to an elevated visceral pain threshold without altering itch behavior (Fig. 6B–D). Additionally, Fgf2 knockdown in these BLA neurons significantly suppressed CRD-induced c-Fos expression in both the BLA and VMH (Fig. 6E–G), indicating that Fgf2 in the BLA regulates VMH neuronal activities. Together, these results provide compelling evidence that Fgf2 in the BLA selectively modulates visceral pain via BLAFgf2+-VMH circuit. Similarly, to investigate whether Notch2 regulates itch through the BLA-DMS neural circuit, we selectively knocked down Notch2 expression in His-labeled BLA neurons projecting to DMS. A mixture of AAV2/9-c-fos-tTA and AAV2/9-DIO-mCherry-Notch2 shRNA or scrambled shRNA was injected into the BLA, while AAV2/R-TRE3g-Cre was delivered into the DMS (Fig. 6H). Compared to the scrambled control, Notch2 knockdown reduced the co-localization of mCherry with Notch2-positive neurons, leading to a significant decrease in the number of scratching bouts without affecting visceral pain behaviors (Fig. 6I–K). Knockdown of Notch2 in these BLA neurons markedly decreased c-Fos expression in both the BLA and DMS following His stimulation (Fig. 6L–N), indicating that Notch2 in the BLA modulates DMS neuronal activities. Under the same experimental conditions, we performed circuit-specific knockout of Fgf2 and Notch2 in female mice. Fgf2 knockdown reduced mCherry co-localization with Fgf2+ neurons and elevated the visceral pain threshold without altering itch (Supplementary Fig. 10A–D). Conversely, Notch2 knockdown reduced mCherry co-localization with Notch2+ neurons and decreased scratching bouts without affecting visceral pain (Supplementary Fig. 10E–H). These findings provide compelling evidence that Notch2 in the BLA specifically regulates itch behaviors through its influence on the DMS. Collectively, these data demonstrate that Fgf2 selectively modulates visceral pain via the BLAFgf2+-VMH circuit, while Notch2 specifically controls itch through the BLANotch2+-DMS pathway. Fgf2 specifically regulates visceral pain through the BLA-VMH neural circuit, whereas Notch2 specifically modulates itch via the BLA-DMS pathway. A Schematic of the viral approach and time course for the selective knockdown of Fgf2 in CRD-labeled BLA cells that project to the VMH. B Representative micrographs showing knockdown of Fgf2 with the corresponding statistical graphs from Scramble and Fgf2-KD. ***P < 0.001, unpaired Student’s t test, n = 6 brain slices from three mice per group. C, D Selective knockdown of Fgf2 elevated visceral pain threshold (C) while leaving itch behavior unaltered (D). **P = 0.024, unpaired Student’s t test, n = 8 mice per group. E Experimental scheme illustrating CRD stimulation applied after Fgf2 knockdown. F, G Knockdown of Fgf2 significantly reduced c-Fos expression in the BLA (F) and VMH (G) following CRD stimulation. ***P < 0.001, unpaired Student’s t test, n = 6 brain slices from three mice per group. H Schematic of the viral approach and time course for the selective knockdown of Notch2 in His-labeled BLA cells that project to the DMS. I Representative micrographs showing knockdown of Notch2 and the corresponding statistical graphs. ***P < 0.001, unpaired Student’s t test, n = 6 brain slices from three mice per group. J, K Selective knockdown of Notch2 specifically decreases the bouts of scratching (J) while leaving visceral pain unaltered (K). ***P < 0.001, unpaired Student’s t test, n = 8 mice per group. L Experimental scheme illustrating His stimulation applied after Notch2 knockdown. M, N Knockdown of Notch2 significantly reduced c-Fos expression in the BLA (M) and DMS (N) following His stimulation. ***P < 0.001, unpaired Student’s t test, n = 6 brain slices from three mice per group. All data are presented as means ± SEM. Scale bar = 100 μm in all panels, ns: no significance. Discussion The present study provides evidence that the BLA plays a role in distinguishing and integrating the sensory components of visceral pain and itch, with the ventromedial hypothalamus and DMS identified as specialized regions involved in the distinct pathways of these sensations. Notably, BLA glutamatergic rather than GABAergic neurons activated by visceral pain and itch exhibit distinct molecular signatures and projection patterns, which modulate visceral pain and itch, respectively (Fig. 7). Graphical abstract of BLA: two distinct neuronal ensembles mediating visceral pain and itch through separate circuit and molecular mechanisms. BLA contains two functionally distinct neuronal populations that specifically mediate visceral pain and itch, respectively. The His-labeled neuronal ensemble is characterized by selective Notch2 expression and projects specifically to the DMS, forming a BLA-DMS circuit that selectively regulates itch responses without affecting visceral pain processing. Conversely, the CRD-labeled neuronal population specifically expresses Fgf2 and projects to the VMH, forming a BLA-VMH pathway that exclusively modulates visceral pain while remaining unresponsive to itch. One of the most important findings is that the BLA is involved in both visceral pain and itch processing. While previous studies have established the BLA’s involvement in diverse physiological functions, including emotional regulation, fear conditioning, and memory consolidation27–31, our findings reveal the functional role of the BLA as a sorting center that differentially regulates visceral pain and itch. Interestingly, the very low proportion of BLA neurons co-activated by visceral pain and itch indicates that these two modalities are represented by largely distinct neuronal ensembles within the BLA. This observation raises a question: is this differential encoding driven by modality-specific sensory processing mechanisms, or by differences in topographical organization? If topographical factors were responsible, delivering pain and itch stimuli to the same anatomical location would recruit highly overlapping BLA neuronal populations. However, when both stimuli were applied to the same site (the nape of the neck) of mice, the overlap between pain- and itch-activated BLA neurons remained very low (8.3%). This finding argues greatly against a topography-based explanation and very likely supports the notion that distinct processing mechanisms underlie visceral pain and itch. Importantly, recent studies have also shown that somatic pain and itch delivered to different anatomical locations recruit distinct neuronal subpopulations in the mPFC and ACC13,14, further supporting our interpretation. Collectively, these converging lines of evidence suggest that distributed brain regions operate as a coordinated network to systematically discriminate between sensory modalities such as pain and itch, thereby ensuring that behavioral responses remain appropriately matched to the intrinsic properties of the stimuli. Our previous findings demonstrate that the PVH differentially processes visceral and somatic pain32, while the PVT selectively modulates visceral pain and anxiety33. As a pivotal nucleus within the limbic system, the BLA possesses extensive afferent and efferent connections, maintaining dense fiber projections with both hypothalamic and thalamic regions34–37. Hence, we propose a hierarchical processing pattern for visceral pain: among PVH, PVT and BLA, pain signals first reach the hypothalamic PVH for initial sorting, while more complex processing involving emotions (i.e., anxiety) or sorting between different types of sensations like pain and itch occurs in higher centers like PVT or BLA. The mPFC, a well-established upstream input to the BLA, contains segregated neural ensembles that separately process somatic pain and itch. These specialized populations likely maintain their functional specificity by projecting to distinct BLA ensembles, thereby potentially enabling the BLA to differentiate between visceral pain and itch sensations. This suggests a hierarchical sensory sorting network in the brain, where the BLA serves as a crucial hub. Together, these findings further support the concept that the brain acts as a central hub for information integration, and different sorting centers likely work together through precisely coordinated mechanisms to generate appropriate responses to complex sensory inputs. The application of multiple innovative methodologies has robustly validated our findings. Recent breakthroughs in molecular profiling technologies have substantially advanced our knowledge of cell types by enabling precise correlation between cellular activity signatures and functional roles. Building upon conventional LCM-seq which analyzes tissue or cells with undefined functions, we developed functional LCM-seq (fLCM-seq), a breakthrough technique for isolating and sequencing single neurons with precisely characterized functional properties. Subsequent transcriptomic analysis has revealed that visceral pain- and itch-responsive neurons in the BLA express Fgf2 and Notch2, respectively. While previous studies have elucidated how pain and itch are differentially encoded within shared brain regions, such as mPFC and ACC13,14, these studies did not delve into the molecular level. The critical knowledge gap regarding precise molecular signatures governing these distinct sensory modalities has now been addressed through our application of fLCM technology. Moreover, the application of function-dependent projection mapping represents another innovation of our methodology. Moving beyond traditional projection tracing methods, this approach maps the divergent axonal projections of visceral pain- and itch-responsive BLA neurons to VMH and DMS, respectively. While previous studies have established distinct anatomical downstream projections of mPFC neuronal populations responding to pain versus itch13, they did not correlate these projections with functional specificity, an aspect our study has now refined to the level of function-dependent projection mapping. These findings demonstrate that such modality-specific projection patterns underlie the differential encoding of visceral pain and itch. Nevertheless, the downstream brain regions involved in the propagation of visceral pain and itch signals beyond the VMH and DMS remain to be fully elucidated. The VMH, as “satiety center”, is a critical node in the hypothalamic network38–41. Studies have demonstrated that the VMH sends efferent projections to the periaqueductal gray (PAG), a key region involved in pain modulation, particularly through its activation in response to the descending pain inhibitory pathway42,43. Importantly, the BLA circuits we described likely interact with a broader visceral sensory network. The parabrachial nucleus (PBN) is a critical hub for ascending visceral information and could provide input to or receive modulation from the BLA44,45. Similarly, the central amygdala (CeA), as a major recipient of BLA outputs and a source of projections to the PAG and PBN, is poised to further process the affective quality of these signals46. For the components of itch sensation, the DMS, as a key component of the basal ganglia, receives projections from other brain regions and indirectly processes the motivation aspects of itch sensation47. Importantly, the potential involvement of additional downstream neural circuits cannot be fully ruled out, highlighting the need for further investigation. Notably, our developed fLCM-seq and function-dependent projection mapping technology exhibits broad applicability beyond visceral pain and itch research, extending to diverse neuroscience domains including affective, cognitive, motivational, and sleep–wake behavioral phenotypes. This methodological advancement enables systematic correlation of transcriptomic signatures with behavioral phenotypes across diverse neural systems. In clinical practice, visceral pain and itch co-occur in conditions like primary biliary cholangitis, chronic kidney disease, and inflammatory bowel diseases48–51. Cholestatic diseases induce itch through bile acid signaling and visceral pain via biliary obstruction52,53. Similarly, chronic kidney disease manifests uremic itch alongside visceral pain from renal stretching or calculi54,55. In inflammatory bowel disease, itch arises from gut-brain axis mediators or anti-TNF therapy56,57. The lack of clear therapeutic targets and well-defined mechanisms underlying this clinical constellation creates a therapeutic impasse, as current peripherally-targeted approaches merely alleviate symptoms without modifying the underlying disease progression or central sensitization processes. Deciphering the central neurocircuitry and molecular drivers of these symptoms is therefore essential for developing transformative treatments. The present work primarily focused on elucidating how the BLA differentially encodes and processes visceral pain and itch at the neural circuit and molecular levels. Given that chronic pain and chronic itch coexist in clinical conditions and involve complex, experience-dependent neuroplasticity, future studies incorporating such comorbidity models will be essential to bridge the gap between basic mechanistic insights and translational application. Another important finding is that BLAFgf2+ neurons specifically regulate visceral pain, while BLANotch2+ neurons are uniquely dedicated to regulating itch. This precise functional dichotomy within the BLA underscores the molecular heterogeneity of its dominant glutamatergic population, identifying Fgf2 and Notch2 as central-specific markers for these distinct sensations. The discovery provides potential specific targets for the intervention of visceral pain and itch. A critical unresolved issue persists: the upstream brain regions of distinct BLA populations, leaving the origins of Fgf2 and Notch2 undetermined. Notably, studies have shown that Fgf13 is involved in the mediation of thermal nociception in nociceptive neurons at the DRG level58. Our findings further emphasize the role of Fgf2 in the BLA in regulating visceral pain, providing theoretical support for the clinical targeting of visceral pain. Notch2 is a key receptor in the Notch signaling pathway. Studies have revealed that cholestatic disorders such as primary biliary cholangitis exhibit elevated Notch2 expression25. Chronic kidney disease-associated itch also exhibits Notch2 overexpression59,60. Our findings further highlight Notch2’s regulatory role in itch processing within the BLA, solidifying its position as a promising therapeutic target for refractory itch conditions. In summary, the present study employs a combination of advanced methodologies, including the Tet-off system, c-Fos immunofluorescence, fLCM-seq, and function-dependent projection tracing, to elucidate the roles of the BLA as a critical hub for sorting visceral pain and itch signals. Our results demonstrate that distinct neural ensembles within the BLA mediate the differentiation between visceral pain and itch. These ensembles exhibit significant heterogeneity in molecular signatures, projection architectures, and associated behaviors. Collectively, these observations yield an understanding of the neural and molecular substrates that govern the brain’s distinct processing of visceral pain versus itch. Moreover, this work provides a theoretical foundation for designing targeted therapeutic interventions and analgesics for visceral pain and itch. Methods Animals Adult male and female C57BL/6 mice (>8 weeks, 20 ~ 25 g) were used in the present study. There are differences between males and females in pain perception61,62, which may be related to the regulatory levels of sex hormones. Recognizing the importance of sex as a biological variable, we extended our experimental validation to include both male and female mice. The animals were housed at the Experimental Animal Centre of Soochow University under standard conditions (12 h light/dark cycle, temperature of 23 ~ 25 °C and humidity of 40 ~ 60%) with free access to food and water. All mice were purchased from the Experimental Animal Center of Soochow University, and all procedures were approved by the Animal Care Committee of Soochow University and were conducted in compliance with the guidelines of the International Association for the Study of Pain. Viruses and stereotaxic surgery Some viruses used in this study were purchased from BrainVTA Co., Ltd. (Wuhan, P.R. China): AAV-Vglut2-GCaMP6s (titer: 5.12 × 1012 gc/mL, serotype: 2/9), AAV-c-fos-tTA (titer: 5.25 × 1012 gc/mL, serotype: 2/9), AAV-TRE3g-mCherry (titer: 5.88 × 1012 gc/mL, serotype: 2/9), AAV-TRE3g-hM3Dq-mCherry (titer: 5.14 × 1012 gc/mL, serotype: 2/9), AAV-TRE3g-hM4Di-mCherry (titer: 4.94 × 1012 gc/mL, serotype: 2/9), AAV-TRE3g-Cre (titer: 2.93 × 1012 gc/mL, serotype: 2/9), AAV-EF1α-DIO-Ypet-2A-mGFP (titer: 5.16 × 1012 gc/mL, serotype: 2/9), AAV-hSyn-EGFP (titer: 5.12 × 1012 gc/mL, serotype: 2/9), AAV-hSyn-DIO-EGFP (titer: 4.88 × 1012 gc/mL, serotype: 2/9), AAV-EF1α-fDIO-mCherry (titer: 4.70 × 1012 gc/mL, serotype: 2/9), AAV-hSyn-Cre (titer: 5.36 × 1012 gc/mL, serotype: 2/R), AAV-hSyn-flp (titer: 1.06 × 1013 gc/mL, serotype: 2/R), AAV-TRE3g-DIO-EYFP (titer: 5.10 × 1012 gc/mL, serotype: 2/9), AAV-EF1α-DIO-axon-GCaMP6s (titer: 5.41 × 1012 gc/mL, serotype: 2/9). Some viruses to knockdown Fgf2 and Notch2 were from PackGene Biotech (Guangzhou, China), and the short-hairpin sequences were 5’-GAAACGAACTGGGCAGTATAA-3’ and 5’-CACACCAACTTGCGCATTAAA-3’ respectively (The other candidate sequences for Fgf2 are 5’-GAGAGGAGTTGTGTCTATCAA-3’ and 5’-GCTTCTAAGTGTGTTACAGAA-3’. The other candidate sequences for Notch2 are 5’-CGAGACCCAGTACAGTGAAAT-3’ and 5’-GCTCCGACTATGTCAACAGTT-3’. We selected the one with the highest knockdown efficiency). The specificity and efficacy of shRNA had been validated and high titers were guaranteed, including: AAV-DIO-mCherry-Fgf2 shRNA (titer: 1.00 × 1013 gc/mL, serotype: 2/9), AAV-DIO-mCherry-Notch2 shRNA (titer: 1.00 × 1013 gc/mL, serotype: 2/9), AAV-DIO-mCherry-scramble shRNA (titer: 1.00 × 1013 gc/mL, serotype: 2/9). The viruses were injected at a volume of 200 nL per site. All viruses were divided into aliquots and kept at −80 °C prior to use. The detailed protocol for stereotaxic injection was presented as follows. Stereotaxic injection was performed as follows: Mice were anesthetized with isoflurane and securely positioned in a stereotaxic frame. The skull was exposed through a midline scalp incision, and the target coordinates (anterior–posterior, medial–lateral, and dorsal-ventral relative to bregma) were determined using a standard mouse brain atlas. A small craniotomy was performed at the target site using a microdrill. A glass micropipette or Hamilton syringe was lowered to the desired depth, and the injection solution (e.g., virus, drug, or tracer) was delivered at a controlled rate (e.g., 0.1 µL/min) using a microinfusion pump. The pipette or syringe was left in place for an additional 5 ~ 10 minutes post-injection to prevent backflow. The scalp was then sutured, and mice were allowed to recover on a heating pad before being returned to their home cages. Proper injection placement was confirmed post-experimentally through histological analysis or imaging. The brain regions targeted in this study were listed below: BLA (AP: −1.25 mm, ML: ±3.05 mm, DV: −4.76 mm); VMH (AP: −1.36 mm, ML: ±0.35 mm, DV: −5.7 mm); DMS (AP: 1.1 mm, ML: ±1.1 mm, DV: −3.0 mm)63–65. The establishment of visceral pain models Visceral pain (specifically refers to intestinal pain) was induced using colorectal distension (CRD) as previously described33. This stimulus evoked acute visceral pain, which was manifested by abdominal contraction and arching of the back in mice. Briefly, under a slight anesthesia, a flexible latex balloon (2 cm) was inserted into the colorectum 3 cm from the mouse anus. The balloon was constructed from a latex glove finger attached to an infusion tube. Each mouse was placed in a transparent box, gently restrained with pressure-sensitive tape for an acclimation period of 0.5 to 1 hour to ensure a fully conscious and stable state before the CRD procedure. Then the CRD stimulation was performed separately with different pressures from 20 mmHg to 80 mmHg. In response to a CRD stimulation, the mice exhibited a single abdominal arch, and each CRD stimulation lasted for 20 seconds. To induce c-Fos expression, the CRD stimulation of 60 mmHg was performed 6 times on the mouse every 3 minutes for 20 seconds. Two hours after the CRD stimulation, the mice were perfused transcardially with saline followed by 4% PFA. The establishment of itch models To establish itch models, mice received intradermal injections of pruritogens (10 μL) into the neck skin: histamine (100 μg; Sigma-Aldrich, St. Louis, MO) or chloroquine (100 μg; Sigma-Aldrich, St. Louis, MO), dissolved in sterile normal saline. Pruritogen concentrations were selected based on established protocols for inducing consistent scratching behavior66. Control animals received equivalent volumes of sterile NS only. Scratching behavior was video-recorded for 30 minutes post-injection, and scratching bouts were quantified in a blinded manner. Immunofluorescent histochemical staining The brain sections were washed with PBS three times (10 minutes each time). For immunofluorescence staining, the brain slices were blocked in 10% normal donkey serum (NDS) for 30 minutes at room temperature and then incubated at 4 °C for 18 ~ 20 h with primary antisera in 0.01 M PBS containing 1% NDS, 0.3% Triton X-100, 0.02% sodium azide, and 0.12% carrageenan (pH 7.4). After three additional PBS washes (10 minutes each), secondary antibodies and 4’,6-diamidino-2-phenylindole (DAPI) in PBS-NDS were added for 2 hours. After three additional washes with PBS (10 minutes each), the sections were air-dried, mounted with coverslips, and stored at −20 °C for subsequent imaging. The primary antibodies used were as follows: anti-c-Fos (1:200, Rabbit, Cell Signaling Technology, Danvers, MA, USA), anti-c-Fos (1:200, Guinea pig, Oasis Biofarm, Hangzhou, Zhejiang, China), anti-Glutamate (1:400, Rabbit, Cell Signaling Technology, Danvers, MA, USA), anti-GABA (1:400, Rabbit, Sigma-Aldrich, St. Louis, MO, USA), anti-Fgf2 (1:300, Rabbit, Abcam, Cambridge, UK), anti-Notch2 (1:300, Rabbit, Cell Signaling Technology, Danvers, MA, USA). The secondary antibodies used were as follows: anti-rabbit Alexa Fluor 488 (1:500, Invitrogen, USA), anti-rabbit Alexa Fluor 555 (1:500, Invitrogen, USA) and anti-rabbit Alexa Fluor 647 (1:500, Invitrogen, USA). Tet-off system-based labeling of visceral pain-specific neurons For activity-dependent labeling of visceral pain-activated neurons in the BLA, mice received doxycycline (Dox; 1 g/500 mL) in drinking water for 3 weeks post-virus delivery. A 36-hour Dox withdrawal period was implemented to establish the labeling window32. During this period, mice were acclimatized in individual transparent chambers for 0.5 ~ 1 hour prior to CRD stimulation. As for CRD stimulation, 60 mmHg force of the CRD stimulation was applied at 3-minute intervals over a 90 minutes trial block for 30 applications of repeated CRD stimulation in sum. Following CRD, mice were returned to their home cages with Dox drinking water to terminate neuronal labeling by CRD stimulation. Tet-off system-based labeling of itch-specific neurons For activity-dependent labeling of itch-activated neurons in the BLA, mice were maintained on Dox in drinking water for 3 weeks post-viral delivery. A 36-hour Dox withdrawal period was then implemented to enable neuronal labeling32. During this window, mice received intradermal injections of histamine (100 μg in 10 μL normal saline; Sigma-Aldrich, St. Louis, MO) into the neck skin66. Following injection, animals were placed in individual observation chambers for 30 minutes to allow spontaneous scratching behavior. After the itch stimulation period, mice were returned to their home cages with Dox-supplemented water to terminate the labeling process. c-Fos immunofluorescent histochemical staining with Tet-off system To simultaneously visualize visceral pain- and itch-activated cells within the same brain sections, we employed a combined approach utilizing the Tet-off system and c-Fos immunofluorescence staining. Briefly, mice received either visceral pain stimulation via CRD (60 mmHg, 30 stimuli at 3-minute intervals over 1.5 hours) or itch stimulation through intradermal histamine injection (10 μL of 1% solution). This dual-method approach enabled precise identification and differentiation of neuronal populations responsive to distinct somatosensory modalities (i.e., visceral pain and itch). Function-dependent chemogenetic manipulation To achieve pathway-specific chemogenetic activation or inhibition within the BLA-VMH or BLA-DMS circuits, a mixture of AAV2/9-c-fos-tTA and AAV2/9-TRE3g-hM3Dq-mCherry or AAV2/9-c-fos-tTA and AAV2/9-TRE3g-hM4Di-mCherry was microinjected bilaterally into the BLA for pathway-specific activation or inhibition. Thirty minutes preceding visceral pain or itch behavioral assessments, either normal saline (NS) or clozapine-N-oxide (CNO; 0.33 mg/mL, 300 nL per hemisphere) was delivered bilaterally into the VMH or DMS at a constant infusion rate of 100 nL/min via internal injector cannulas. Bilateral guide cannulas (RWD, Shenzhen, China) were stereotaxically secured above the target brain structures according to precise coordination parameters, utilizing distinct configurations for the VMH (O.D. 0.48 × I.D. 0.34 mm, side-by-side distance 0.7 mm; RWD, Shenzhen, China) and the DMS (O.D. 0.48 × I.D. 0.34 mm, side-by-side distance 2.2 mm; RWD, Shenzhen, China). To maintain patency and prevent occlusion, a dummy cannula (O.D. 0.30 × I.D. 0.14 mm; RWD, Shenzhen, China) was inserted into each guide cannula prior to testing. The implantation coordinates of the cannula corresponded precisely to the stereotaxic coordinates for the target brain region. The internal injectors were coupled via polyethylene lines to 10 μL microsyringes (Gaoge, Shanghai, P.R. China) driven by an automated microinfusion pump (KD Scientific, LEGATO130, USA), allowing microinjections to be executed continuously over a 10 min timeframe. Following complete volume delivery, the internal injectors were left in situ within the target parenchymal tissue for an additional 2 ~ 3 min to guarantee optimal drug diffusion. Fiber photometry recording Fluorescence GCaMP signals were monitored using a commercial fiber photometry setup (Thinker Tech, QAXK-FPS-SS-MC-LED, Nanjing, P.R. China) to assess the functional dynamics of BLA somas and their axonal projections32. Briefly, a 470-nm excitation laser was deflected via a dichroic mirror, focused through a ×10 objective lens, and linked to an optical commutator. This assembly delivered the laser beam (20 ~ 40 μW) to the indwelling cannula via a 2-m patch cord (0.37 NA, 200 μm OD, Thinker Tech, Nanjing, P.R. China). Concurrently, a 405-nm channel was recorded as an isosbestic reference to eliminate motion artifacts from the 470-nm signal. Calcium signals of CRD stimulation were recorded in 470 nm channel over a time window spanning from 2 s before (−2–0 s) to 10 s after (0–10 s) stimulus onset. While as for His stimulation, the calcium signal was recorded at the moment of scratching for 2 s ranged from (−2–0 s) to 10 s. The data of ΔF/F were analyzed by custom-written MATLAB codes (MATLAB R2017b, MathWorks, America). For recording calcium signals of the BLA glutamate neurons, AAV2/9-Vglut2-GCaMP6s was injected into BLA with optical fiber implanted to record calcium signals under the stimulation of CRD and His. For recording calcium signals of axons from BLA CRD-labeled neurons to VMH under the stimulation of CRD or His, a mixture of AAV2/9-c-fos-tTA and AAV2/9-EF1α-DIO-axon-GCaMP6s was microinjected into the BLA, and AAV2/R-TRE3g-Cre was microinjected into VMH with optical fiber implanted. For recording calcium signals of axons from BLA His-labeled neurons to DMS under the stimulation of CRD or His, a mixture of AAV2/9-c-fos-tTA and AAV2/9-EF1α-DIO-axon-GCaMP6s was microinjected into the BLA, and AAV2/R-TRE3g-Cre was microinjected into DMS with optical fiber implanted. Function-dependent laser capture microdissection coupled with RNA sequencing (fLCM-Seq) To investigate transcriptome discrepancies in BLA cells selectively responsive to visceral pain and itch correspondingly, we utilized function-dependent laser microdissection capture (LCM) coupled with RNA sequencing (fLCM-Seq)32 through a three-step procedure: Function-dependent labeling BLA neurons were labeled in an activity-dependent manner by combining the Tet-off system with staining. For itch-activated neuronal labeling, a mixture of AAV2/9-c-fos-tTA and AAV2/9-TRE3g-mCherry was microinjected into the BLA. Post-injection, mice received doxycycline-supplemented drinking water (Dox, 1 g/500 mL) for 3 weeks. To establish a window for activity-dependent induction, Dox water was replaced with standard drinking water for 36 h. During this period, 10 μL of histamine (100 μg, Sigma, St. Louis, MO) dissolved in normal saline was injected into the neck skin of each mouse intradermally. After injection of histamine, mice were placed into a separate transparent box for 30 minutes to scratch freely to label the neurons activated by itch with mCherry. Following a 36-h recovery period on Dox water, mice underwent visceral pain induction. CRD at an intensity of 60 mmHg was applied for 30 cycles (once every 3 min over a 1.5 h session). Ninety minutes post-CRD, mice were anesthetized and transcardially perfused with 0.9% saline and 4% paraformaldehyde. Coronal brain slices (10 μm) were prepared for immunohistochemical evaluation of mCherry and c-Fos, yielding distinct mCherry-labeled (itch) and EGFP-labeled (visceral pain) BLA subsets. Laser capture microdissection of CRD- or His-labeled neurons LCM was executed utilizing the PALM platform (Zeiss Microimaging, Munich, Germany) to isolate three distinct neuronal populations: mCherry-positive, c-Fos-positive, and mCherry & c-Fos double-positive neurons. For each cohort, ~300 individual cells were isolated via single-cell laser dissection and harvested into 200 μL adhesive-capped collection tubes (Carl Zeiss, Cat. No. 415190-9191-000, Jena, Germany) pre-filled with 10 μL lysis buffer. Tubes were subsequently sealed with Parafilm, and cDNA libraries were constructed adhering to the Smart-3SEQ protocol. RNA-Seq and data analyses The size distribution of the cDNA libraries was verified via an Agilent 2100 Bioanalyzer paired with a High Sensitivity D1000 reagent kit (Agilent Technologies, Santa Clara, CA, USA), with samples stored at −20 °C prior to sequencing. High-throughput sequencing was executed on an Illumina platform (Illumina, San Diego, CA, USA) in a 2 × 150 bp paired-end configuration. Bioinformatic processing of the RNA-seq dataset was conducted using the standard Seurat (v4.3.0) pipeline. Transcripts present in at least one individual cell were maintained for downstream filtration. Normalization of the expression matrices was executed using the default settings of the NormalizeData function. Following the selection of highly variable genes, principal component analysis (PCA) was performed, and cell clustering was visualized via t-SNE. DEG was evaluated via DESeq2 (v1.32.0) utilizing strict filters (log2 fold change > 4; p value < 0.05). For CRD-labeled cells, differential expression was analyzed between: (1) CRD-labeled versus His-labeled cells, and (2) CRD-labeled versus CRD & His co-labeled cells. CRD-specific DEGs were identified by intersecting these two comparison sets. The same analytical approach was applied to identify DEGs in the remaining cell populations. Drug administration For chemogenetic manipulation, CNO administration was performed through either intraperitoneal injection (0.33 mg/mL, 0.2 mL) or bilateral intracerebral microinjection (0.33 mg/mL, 300 nL per site). Systemic administration was achieved via intraperitoneal delivery, while localized CNO application was accomplished through stereotaxically guided bilateral microinjections into target brain regions. For agonist experiments, Heparin (Fgf2 agonist) and Jagged-1 (Notch2 agonist), both purchased from Sellect Inc., were administered via bilateral intracerebral microinjection (100 µM, 300 nL per site). The drug concentrations employed in this study were based on preliminary experiments and established protocols from prior research. The injections were performed using a microinjection syringe, with cannulas remaining in situ for an additional 2-3 minutes post-injection to ensure optimal drug diffusion. Statistical analyses The counting was performed manually by an observer who was blinded to the treatment conditions. Statistical analyses were performed using GraphPad Prism software version 8.0 (GraphPad Software Inc., San Diego, CA), and all data are expressed as mean ± standard error of the mean. Statistical significance was evaluated by the student’s t test or two-way analysis of variance followed by Bonferroni’s test for multiple comparisons. The “n” applied in these analyses represents the number of mice, slices, or cells. Statistical significance was determined using a two-sided p value of <0.05. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supplementary Information Reporting Summary Transparent Peer Review file Source data Source Data